8-K: Picard Medical's Emperor TAH Achieves First In Vivo Implants

Picard Medical's subsidiary, SynCardia, successfully completed the first in vivo implantations of its next-generation Emperor Total Artificial Heart, marking a significant advancement.

Summary

• Picard Medical, Inc. (NYSE American: PMI) announced its wholly-owned subsidiary, SynCardia Systems LLC, completed the first in vivo implantations of the Emperor Total Artificial Heart (TAH).
• This marks a major milestone for the Emperor platform, intended as the successor to the clinically proven, FDA-approved SynCardia Total Artificial Heart (STAH).
• The Emperor TAH was successfully implanted in three pre-clinical models, and each model was taken off bypass without any issues.
• Throughout the observation periods, the device provided full and stable blood circulation, used energy efficiently, and operated without technical problems.
• The device performed in a way that closely mirrors a natural human heart, producing stable hemodynamics, showing physiologic preload sensitivity, and maintaining afterload independence, reflecting the Frank Starling response.
• All results were consistent with Picard Medical's laboratory performance goals for the Emperor platform.

Sentiment

Score: 9

Explanation: The successful first in vivo implantations of a next-generation, fully implantable total artificial heart represent a major technological and clinical milestone, reinforcing the company's leadership and opening new market opportunities.

Positives

• Successful completion of the first in vivo implantations of the next-generation Emperor Total Artificial Heart.
• Positive outcomes observed in three separate pre-clinical models, with devices providing full and stable blood circulation, efficient energy use, and no technical problems.
• The Emperor TAH performed similarly to a natural human heart, exhibiting stable hemodynamics, physiologic preload sensitivity, and afterload independence (Frank Starling response).
• Results were consistent with Picard Medical's laboratory performance goals for the Emperor platform.
• Strengthens SynCardia's position as a global leader in total artificial hearts and validates the Emperor platform's potential.
• The Emperor platform is designed to expand the total artificial heart market by offering a fully implantable system with improved performance, energy efficiency, and patient usability.

Risks

• Forward-looking statements involve risks and uncertainties that could cause actual results to differ from the forward-looking statements.
• Numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC.

Future Outlook

SynCardia will continue with additional pre-clinical studies to refine the final system parameters. The Emperor platform is designed to expand the total artificial heart market by delivering a fully implantable system with improved performance, energy efficiency, and patient usability, with the potential to become a fully implantable alternative to heart transplantation.

Management Comments

• "We are excited by these initial data. The successful completion of these first implantations brings SynCardia back to the forefront of innovation in total artificial heart technology." Patrick NJ Schnegelsberg, CEO of Picard Medical.
• "This milestone strengthens our position as the global leader in total artificial hearts and is yet another step that validates the potential of the Emperor platform." Patrick NJ Schnegelsberg, CEO of Picard Medical.
• "Our very positive experience with implanting the next-generation TAH in three separate in vivo models confirms that the Emperor platform is progressing as designed and confirms its potential to become a fully implantable alternative to heart transplantation." Andre R. Simon, MD, PhD, FRCS, Vice President of Medical Affairs.
• "The performance characteristics observed in each of these acute experiments validate key engineering choices and support continued program acceleration for this novel device which could be an even further improvement to a patient's quality of life." Andre R. Simon, MD, PhD, FRCS, Vice President of Medical Affairs.

Industry Context

This announcement positions Picard Medical and its SynCardia subsidiary at the forefront of innovation in the total artificial heart market, a critical area for patients with end-stage heart failure. The development of a fully implantable, driverless TAH like the Emperor platform represents a significant leap beyond existing technologies, potentially expanding the market and offering a more patient-friendly alternative to heart transplantation. SynCardia already holds a leadership position with the FDA-approved SynCardia Total Artificial Heart, which has over 2,100 implants globally.

Comparison to Industry Standards

• The Emperor TAH is positioned as the next-generation successor to the clinically proven, FDA-approved SynCardia Total Artificial Heart (STAH), which is the world's first and most widely used artificial heart with over 2,100 implants across 27 countries.
• The successful in vivo implantations demonstrate performance consistent with Picard Medical's laboratory goals, mirroring the natural Frank Starling response of a human heart.
• The Emperor platform aims to improve upon existing artificial heart technology by being fully implantable, offering improved performance, energy efficiency, and patient usability, which would be a significant advancement over current external driver systems.

Stakeholder Impact

• Shareholders: Positive impact due to significant technological advancement, potential market expansion, and strengthened leadership position, which could lead to increased future revenue and profitability.
• Patients with End-Stage Heart Failure: Potential for a fully implantable, more effective, and user-friendly alternative to heart transplantation, significantly improving quality of life.
• Medical Professionals/Hospitals: New, advanced treatment option for end-stage heart failure, potentially simplifying management compared to current devices.
• Employees: Positive impact from successful R&D, reinforcing the company's innovative culture and market position.

Next Steps

• SynCardia will continue with additional pre-clinical studies to refine the final system parameters for the Emperor platform.

Key Dates

Recommendation

The successful first in vivo implantations of the Emperor Total Artificial Heart represent a pivotal technological breakthrough for Picard Medical. This next-generation, fully implantable device has the potential to significantly expand the total artificial heart market and solidify SynCardia's global leadership. The positive pre-clinical results, demonstrating natural heart-like function and efficiency, de-risk a critical development stage. This milestone suggests a strong future growth trajectory and enhanced competitive advantage in addressing end-stage heart failure, making the stock a compelling "Strong Buy" for long-term investors.

Keywords

Total Artificial Heart, TAH, Emperor TAH, SynCardia, Picard Medical, PMI, medical device, heart failure, cardiovascular, in vivo, pre-clinical, implantable heart